海普瑞(09989.HK):旗下INHIX A取得北馬其頓批准
格隆匯 4 月 13日丨 海普瑞(09989.HK)宣佈,旗下全資附屬公司深圳市天道醫藥有限公司生產的Inhixa(集團依諾肝素鈉注射液領先藥物之一)已獲得北馬其頓共和國之藥物及醫療器械機構批准上市銷售。
目前,集團生產的依諾肝素鈉注射液產品,已獲准在全球逾50個國家上市銷售,並在21個國家實現銷售,同時亦可向其他15個國家的客户供應依諾肝素鈉注射液。董事會認為過去三年海外市場的銷售及安全數據的良好反饋已讓集團獲得更多市場份額,董事會預期是次的註冊批准將進一步加速公司製劑業務的全球化佈局推進。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.